Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?

References

• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–482.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–1835.
   PubMed Web of Science ®Google Scholar
• Amgen. Imlygic (talimogene laherparepvec) suspension for intralesional injection: US presecribing information; 2015 [cited 2018 Aug 2]. Available from: http://www.fda.gov
   Google Scholar
• Burke EE, Zager JS. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Metab Toxicol. 2018;14:469–473.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW. Oncolytic virotherapy: a contest between apples and oranges. Mol Ther. 2017;25:1107–1116.
   PubMed Web of Science ®Google Scholar
• Hamid O, Hoffner B, Gasal E, et al. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother. 2017;66:1249–1264.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
   PubMed Web of Science ®Google Scholar
• Gangi A, Zager JS. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2017;16:265–269.
   PubMed Web of Science ®Google Scholar
• Sloot S, Rashid OM, Sarnaik AA, et al. Developments in intralesional therapy for metastatic melanoma. Cancer Control. 2016;23:12–20.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.
   PubMedGoogle Scholar
• Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12:6737–6747.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6:941–949.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23:4169–4177.
   PubMed Web of Science ®Google Scholar
• Perez M, Miura J, Holstein A, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single institution experience. Ann Surg Oncol. Forthcoming.
   Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36:1658–1667.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(1109–1119):e1110.
   Google Scholar
• Long GV, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(supplement 15):9568.
   Web of Science ®Google Scholar
• Andtbacka RH, Dummer R, Gyorki DE, et al. Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL). J Clin Oncol. 2018;36(supplement):Abstract9508.
   Google Scholar
• Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19:1913–1922.
   PubMed Web of Science ®Google Scholar
• Viralytics. About CAVATAK(R); 2018 [cited 2018 Aug 21]. Available from: https://www.viralytics.com/our-pipeline/cavatak/cavataktm/
   Google Scholar
• Andtbacka RH, Curti B, Kaufman HL, et al. Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. J Clin Oncol. 2015;33(supplement_15):9030.
   Web of Science ®Google Scholar
• Andtbacka RH, Curti B, Hallmeyer S, et al. Phase II calm extension study: coxsackievirus A21 delivered intratumorally to patients with andvanced melanoma induces immune-cell infiltration in the tumor microenvironment. J Immunother Cancer. 2015;3(supplement_2):P343.
   Google Scholar
• Curti B, Richards J, Faries MB, et al. The MITCI (phase1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma. Annals of Oncology. 2016;27(supplement_6):1051PD.
   Google Scholar
• Curti B, Richards J, Hallmeyer S, et al. Abstract CT114: the MITCI (Phase 1b) study: a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treament. Paper presented at: Proceedings: AACR Annual Meeting 2017; 2017 Apr 1–5; Washington (DC).
   Google Scholar
• Silk AW, Kaufman HL, Gabrail N, et al. Abstract CT026: phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: interim results of the CAPRA clinical trial. Paper presented at: AACR Annual Meeting 2017; 2017 Apr 1–5; Washington (DC).
   Google Scholar
• Eissa IR, Naoe Y, Bustos-Villalobos I, et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol. 2017;7:149.
   PubMedGoogle Scholar
• Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol. 2012;13:1842–1851.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Gross ND, Nemunaitis J, et al. Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety and efficacy in HSV+/HSV- patients with refractory and superficial cancers. J Clin Oncol. 2014;32(supplement_15):6082.
   Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Agarwala SS, et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J Clin Oncol. 2017;35(supplement_15):9510.
   Google Scholar
• SillaJen. Pexa-Vec (JX-594); 2016 [cited 2018 Aug 21]. Available from: http://www.sillajen.com/eng/sub/eng_sub.aspx?s_code=0201000000
   Google Scholar
• Anthoney A, Samson A, West E, et al. Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity. J Clin Oncol. 2018;36(supplement):Abstract 3092.
   Google Scholar
• Oncolys. Telomelysin(R) (OBP-301); 2018 [cited 2018 Aug 21]. Available from: https://www.oncolys.com/en/pipeline/telomelysin.html
   Google Scholar
• Kishimoto H, Urata Y, Tanaka N, et al. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther. 2009;8:3001–3008.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010;18:429–434.
   PubMed Web of Science ®Google Scholar
• Oncolytics. What is REOLYSIN(R). Calgary, AB: Oncolytics Biotech Inc; 2018.
   Google Scholar
• Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–7137.
   PubMed Web of Science ®Google Scholar
• Galanis E, Markovic SN, Suman VJ, et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998–2003.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Roulstone V, Twigger K, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012;18:2080–2089.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Fountzilas C, Moseley J, et al. A phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017;79:697–703.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Kowalsky S, et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front Immunol. 2017;8:555.
   PubMed Web of Science ®Google Scholar